CSL Ltd. - ADR
CSLLY - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$65.99B
Close$
Earnings Call Q4 2023
August 15, 2023 - AI Summary
CSL delivered strong full-year results, with revenue up 31% at constant currency and NPATA of $2.6 billion, up 20%.
The CSL Behring business saw strong growth in its Ig franchise, with sales up 21%. Plasma collections reached record levels, and the company dosed its first patients with HEMGENIX, a gene therapy for hemophilia B.
CSL Seqirus achieved strong sales growth, driven by FLUCELVAX, which was up 30%. The company also signed a licensing agreement with Arcturus Therapeutics for next-generation mRNA vaccine technology.
Exclusive for Stockcircle Pro members
Sign up
$25.52
25.9% downside
Current Fair Value
25.9% downsideOvervalued by 25.9% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $65.99 Billion |
|---|---|
| Enterprise Value | $75.38 Billion |
| Annual dividend | $0.71 |
| Dividend yield | 2.01% |
| Earnings per Share | $-1.34 |
| Beta | 0.08 |
| Outstanding Shares | 1,915,647,916 |
Return
| Return on Equity | 3.04% |
|---|---|
| Return on Assets | 1.34% |
| Return on Invested Capital | 28.99% |
Valuation & Multiples
| P/E Ratio | -26.23 |
|---|---|
| PEG | 6.73 |
| Price to Sales | 2.15 |
| Price to Book Ratio | 4.31 |
| Enterprise Value to Revenue | 2.42 |
| Enterprise Value to EBIT | 9.19 |
| Enterprise Value to Net Income | 167 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | 0.74 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 17, 2026
EPS
-$1.56
ReportedRevenue
$7.44 B
ReportedInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 0.00% |
|---|---|
| Total Invested | $17,505▼ 97.09% |
| Investors Holding | 3▼ 3.00% |
About CSL Ltd.
29,000 employees
CEO: Paul Perreault
CSL Limited is a global biopharmaceutical enterprise engaged in the discovery, development, production, marketing, and distribution of a wide array of medicinal and related products. Its operations span key markets including Australia, t...